MaxCyte, Inc.
MXCT
Positions held
Your positionsMXCT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $105.27M | Enterprise value | $16.83M | Trailing P/E | — | Forward P/E | -4.16 |
| PEG | — | Price / book | 0.68 | Beta | 1.49 | Dividend yield | 0.00% |
| Revenue growth | -14.5% | Earnings growth | — | Gross margin | 79.2% | Operating margin | -140.7% |
| Profit margin | -114.8% | ROE | -20.4% | ROA | -10.6% | Debt / equity | 0.11 |
| Current ratio | 12.26 | Free cash flow | -$13.14M | Analyst recommendation | none | Mean target | $4.11 |
| 52w high | $1.87 | 52w low | $0.64 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $7.3M | $9.7M | $7.3M | $6.8M | $8.5M |
| Op margin | -140.7% | -64.1% | -105.1% | -162.4% | -167.2% |
| Net income | -$8.9M | -$4.8M | -$9.6M | -$12.4M | -$12.4M |
| Gross margin | 77.0% | 83.7% | 77.9% | 76.6% | 82.1% |
| Gross profit | $5.6M | $8.1M | $5.7M | $5.2M | $7.0M |
| Operating income | -$10.2M | -$6.2M | -$7.7M | -$11.1M | -$14.2M |
- Revenue -25% vs prior quarter ($7.3M vs $9.7M).
- Gross margin 77% (was 83.7% prior quarter).
- Operating margin compressed to -140.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $33.0M | $38.6M | $41.3M | $44.3M | — |
| Op margin | -137.1% | -132.5% | -117.0% | -61.8% | — |
| Net income | -$44.6M | -$41.1M | -$37.9M | -$23.6M | — |
| Gross margin | 81.2% | 81.6% | 88.5% | 88.5% | — |
| Gross profit | $26.8M | $31.5M | $36.5M | $39.2M | — |
| Operating income | -$45.3M | -$51.2M | -$48.3M | -$27.4M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?
2026-09-23 · MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
2026-09-11 · MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-19 · MaxCyte (MXCT) Q2 2026 Earnings Call Transcript
2026-08-19 · MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
2026-08-13 · MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ...
2026-08-13 · MaxCyte, Inc. Q2 2026 Earnings Call Summary
2026-08-13 · MaxCyte Q2 Earnings Call Highlights
2026-08-12 · MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates
2026-08-12 · MaxCyte Reports Second Quarter 2026 Financial Results
2026-08-05 · Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
2026-07-21 · MaxCyte Enters Technology License Partnership With Genentech
Price (daily)
Full chart · RSI · MACD · patterns